TOP > News Release > list in 2008
- Guide to Category Symbols
Corporate
R&D
Products
Others
-
- Welchol(R) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus"
-
- Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
- Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
-
- Luitpold Pharmaceutical's INJECTAFER(TM)
(ferric carboxymaltose injection) receives non-approvable letter from FDA - Luitpold Pharmaceutical's INJECTAFER(TM)
-
- The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
Receives Approval for Manufacture and Marketing - The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
-
- Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
DAIICHI SANKYO presses ahead with European expansion - Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
-
- FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention - FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
-
- Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
Investigational Oral Antiplatelet Drug, Prasugrel, to European
Medicines Agency - Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
-
- DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
(Stock Acquisition Rights) as Remuneration - DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
-
- FDA Advisory Committee Supports Favorable Risk-Benefit Profile for Injectafer(TM)(Ferric Carboxymaltose Injection) Under Certain Indications for Use
-
- Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as
Remuneration- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as
-
- Broad-spectrum Oral Antibacterial Agent
Gracevit(R) tablets 50mg/fine granules 10%
Receives Approval for Manufacturing and Marketing - Broad-spectrum Oral Antibacterial Agent
-
- Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
-
- Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
Drug, Prasugrel, with U.S. Food and Drug Administration
If Approved for Marketing in the United States, Trade Name Will be Effient(TM) - Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
